H
Harvard Bioscience Inc (HBIO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
$8.91
-0.48 (-5.11%)
Market Cap: $42.94M
Last updated: Nov 17, 2026 at 11:03 AM ET
Harvard Bioscience Inc (HBIO) Valuation Multiples
Harvard Bioscience (HBIO) trades at 0.5x sales and 8.0x book value. Its forward P/E is 15.1x.
Current Multiples
Its enterprise value is 117.4x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 15.1x |
| Price to sales | 0.5x |
| Price to book | 8.0x |
| EV/EBITDA | 117.4x |
| PEG | N/A |
| FCF yield | -7.8% |
Valuation History
Over the 8 of the 10 year ends shown that have a P/E, its P/E ranged from 21.6x in 2018 to 48.8x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.69 | N/A | N/A | 2.2x |
| 2024 | $21.10 | N/A | 0.4x | 0.1x |
| 2023 | $53.50 | 46.9x | N/A | N/A |
| 2022 | $27.70 | 33.0x | N/A | 16.0x |
| 2021 | $70.50 | 39.6x | N/A | N/A |
| 2020 | $42.90 | 48.8x | 2.6x | 21.7x |
| 2019 | $30.50 | 28.2x | N/A | 1.4x |
| 2018 | $31.80 | 21.6x | N/A | N/A |
| 2017 | $33.00 | 38.8x | N/A | N/A |
| 2016 | $30.50 | 26.8x | N/A | N/A |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HBIO
What is HBIO's forward P/E ratio?
Harvard Bioscience has a forward P/E ratio of 15.1x.
Is HBIO stock overvalued?
GNG's valuation label for HBIO is Overvalued.
What is HBIO's price to sales ratio?
Harvard Bioscience has a price to sales ratio of 0.5x.
HBIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts